Civic Intelligence

Grace Science Foundation

990 • Fiscal year 2018 • EIN 46-5727883

Jan 01, 2018 to Dec 31, 2018 • Filed on May 15, 2019

Organization ProfileWWW.GRACESCIENCE.ORG
235 Kansas Street Suite 200San Francisco, CA 94103

(415) 255-7666

Siviq Scores

Precomputed percentiles for this filing year versus similar nonprofits in the same peer cohort.

Liabilities / Assets

14th percentile

0.00x

Tied with the lowest-debt nonprofits in its peer group.

2018 filings • 501(c)3 • $1M-$5M nonprofits • Source year 2018

Liabilities / Revenue

14th percentile

0.00x

Tied with the lowest-debt nonprofits in its peer group.

2018 filings • 501(c)3 • $1M-$5M nonprofits • Source year 2018

Net Margin

67th percentile

10%

Higher net margin than 67% of similar nonprofits.

2018 filings • 501(c)3 • $1M-$5M nonprofits • Source year 2018

Top Officer Pay

35th percentile

$0

Higher top officer pay than 35% of similar nonprofits.

Top officer pay equals 0.0% of source-year revenue.

2018 filings • 501(c)3 • $1M-$5M nonprofits • Source year 2018

Asset Growth

60th percentile

4.1%

Faster asset growth than 60% of similar nonprofits.

2018 filings • 501(c)3 • $1M-$5M nonprofits • Annualized from 2017 to 2018

Revenue Growth

10th percentile

-28%

Faster revenue growth than 10% of similar nonprofits.

2018 filings • 501(c)3 • $1M-$5M nonprofits • Annualized from 2017 to 2018

Balance Sheet
Liabilities / Assets14th percentile

Assets

Up

$2,196,374

Up $87,150 (+4.1%) from 2017

Net Assets

Up

$2,196,374

Up $103,650 (+5.0%) from 2017

Liabilities

Down

$0

Down $16,500 (-100%) from 2017

Revenue And Expenses
Liabilities / Revenue14th percentileNet Margin67th percentile

Revenue

Down

$1,199,988

Down $477,119 (-28%) from 2017

Expenses

Up

$1,074,064

Up $153,550 (+17%) from 2017

Net Income

Down

$125,924

Down $630,669 (-83%) from 2017

Historical Trend

Balance Sheet Trend

Asset Growth60th percentile

The highlighted filing sits inside the broader history for assets, liabilities, and net assets.

$4.0M$3.0M$2.0M$1.0M$0Assets 2014: $603,778Liabilities 2014: $0Net Assets 2014: $603,7782014Assets 2015: $1,605,814Liabilities 2015: $0Net Assets 2015: $1,605,8142015Assets 2016: $1,336,131Liabilities 2016: $0Net Assets 2016: $1,336,1312016Assets 2017: $2,109,224Liabilities 2017: $16,500Net Assets 2017: $2,092,7242017Assets 2018: $2,196,374Liabilities 2018: $0Net Assets 2018: $2,196,3742018Assets 2019: $2,889,615Liabilities 2019: $2,201Net Assets 2019: $2,887,4142019Assets 2020: $2,884,506Liabilities 2020: $386Net Assets 2020: $2,884,1202020Assets 2021: $3,128,030Liabilities 2021: $29,929Net Assets 2021: $3,098,1012021Assets 2022: $3,183,591Liabilities 2022: $51,224Net Assets 2022: $3,132,3672022Assets 2023: $2,790,274Liabilities 2023: $42,997Net Assets 2023: $2,747,2772023Assets 2024: $2,224,370Liabilities 2024: $1,004Net Assets 2024: $2,223,3662024

Highlighted filing

2018

Assets$2,196,374
Liabilities$0
Net Assets$2,196,374
Open 2018 Filing

Operations Trend

Revenue Growth10th percentile

Revenue, expenses, and net income across loaded years, with this filing highlighted.

$2.0M$1.0M$0-$1.0MRevenue 2014: $664,490Expenses 2014: $60,712Net Income 2014: $603,7782014Revenue 2015: $1,560,381Expenses 2015: $558,345Net Income 2015: $1,002,0362015Revenue 2016: $600,124Expenses 2016: $869,807Net Income 2016: -$269,6832016Revenue 2017: $1,677,107Expenses 2017: $920,514Net Income 2017: $756,5932017Revenue 2018: $1,199,988Expenses 2018: $1,074,064Net Income 2018: $125,9242018Revenue 2019: $1,561,302Expenses 2019: $839,395Net Income 2019: $721,9072019Revenue 2020: $1,454,180Expenses 2020: $1,452,901Net Income 2020: $1,2792020Revenue 2021: $1,327,113Expenses 2021: $1,113,132Net Income 2021: $213,9812021Revenue 2022: $1,236,228Expenses 2022: $1,218,482Net Income 2022: $17,7462022Revenue 2023: $826,626Expenses 2023: $1,289,174Net Income 2023: -$462,5482023Revenue 2024: $943,011Expenses 2024: $1,519,386Net Income 2024: -$576,3752024

Highlighted filing

2018

Revenue$1,199,988
Expenses$1,074,064
Net Income$125,924
Open 2018 Filing
Jump To
Filing Snapshot
Filing Period
Jan 1, 2018 to Dec 31, 2018
Signed
May 15, 2019
Return Version
2018v3.1
Gross Receipts
$1,204,078
Mission and Program Overview

Mission

The mission of the foundation is to support and fund the development of life-saving treatment for patients that are deficient in the n-glycanese enzyme and those suffering from related genetic diseases. The activities of the foundation will involve providing grant funding to hospitals and medical research facilities which are conducting medical research in various fields relating to the search for understanding and treatment of this condition, and fostering collaboration between academia, research institutions, hospitals, private companies, and governmental agencies.

The mission of the foundation is to support and fund the development of life-saving treatment for patients that are deficient in the n-glycanese enzyme and those suffering from related genetic diseases.

Balance Sheet Detail
LineBeginningEndChange
Assets
Rtn Earn Endowment Incm Other Fnds$2,092,724$2,196,374▲ $103,650
Cash and Non-Interest-Bearing Accounts$2,109,224$2,192,300▲ $83,076
Investments in Publicly Traded Securities-$4,074-
Pd in Cap Srpls Land Bldg Eqp Fund$0$0→ $0
Cap Stk Tr Prin Current Funds$0$0→ $0
Total Assets$2,109,224$2,196,374▲ $87,150
Liabilities
Grants Payable$16,500$0▼ $16,500
Total Liabilities$16,500$0▼ $16,500
Net Assets / Fund Balance
Total Net Assets Fund Balance$2,092,724$2,196,374▲ $103,650
Total Liabilities and Net Assets / Fund Balance$2,109,224$2,196,374▲ $87,150
Compensation and Service Providers
Top Officer Pay35th percentile

Board Members and Trustees

NameTitle
Matthew WilseyPresident
Chelsea ClintonDirector
Elle StephensDirector
J Taylor CrandallDirector
Pete BrigerDirector
Egon DurbanChief Financial Officer
Ken DrazanSecretary
Revenue and Support

Revenue Composition

Contributions and Grants
$1,187,802
Program Service Revenue
$0
Investment Income
$12,186
Other Revenue
$0
All Other Contributions
$1,187,802
Change in Net Assets
$125,924

Noncash Contribution Practices

Property subject to holding requirements
No
Reviewed unusual noncash gifts
No
Third parties used for noncash contributions
No

Noncash Contributions

Contribution TypeContribution CountReported AmountValuation Method
Securities Publicly Traded3$30,437Fair Market Value
Total Noncash Contributions3$30,437-
Expenses and Functional Allocation

Major Expense Lines

Line ItemAmount
Grants and Similar Amounts Paid$898,851
Other Expenses$175,213
Professional Fundraising Fees$0
Salaries, Compensation, and Employee Benefits$0
Total Fundraising Expense$0

Functional Expense Allocation

Line ItemProgramManagementFundraisingTotal
Grants to Domestic Orgs$861,351--$861,351
Fees for Services Other-$81,250-$81,250
Travel$36,552$5,439-$41,991
Foreign Grants$37,500--$37,500
Fees for Services Legal-$12,413-$12,413
Office Expenses$861$11,225-$12,086
Advertising-$8,760-$8,760
Fees for Services Accounting-$4,275-$4,275
Insurance-$955-$955
Other Expenses-$160-$160
Total Functional Expenses$936,264$137,800$0$1,074,064
International Activity

Grant and Assistance Recipients

RecipientLocationCategoryPurposeAmount
Stanford UniversityPalo Alto, CA501(c)(3)Ngly1 Work in Bertozzi/snyder/steinmetz Labs & Natural History Protocol Development$268,187
Baylor College of MedicineHouston, TX501(c)(3)Ngly1 Work in Jafar-nejad Lab$178,158
Salk Institute for Biological StudiesLa Jolla, CA501(c)(3)Ngly1 Work in Gage Lab$124,215
Perlara PbcS San Francisco, CA501(c)(3)Assay Development & Compound Screening$100,000
University of Texas Southwestern Medical CenterDallas, TX-Ngly1 Work in Yan Lab$71,741
The Jackson LaboratoryBar Harbor, ME501(c)(6)Ngly1 Work With Cat Lutz$50,000
Broad InstituteCambridge, MA501(c)(3)Cmap Study & Genetic Sequencing$39,050
University of Massachusetts Medical SchoolWorcester, MA501(c)(6)Ngly1 Work in Gao Lab$30,000

International Summary

Offices
0
Employees
0
Spending
$0

International Compliance

Activity in boycott countries
No
Foreign corporation ownership
No
Foreign partnership interest
No
Interest in foreign trust
No
Passive foreign investment company interest
No
Transfers to foreign corporations
No
Fundraising, Events, and Gaming
Fundraising activities
No
Gaming activities
No
Professional fundraiser used
No

Fundraising and Gaming Totals

Line ItemAmount
Professional Fundraising Fees$0
Political and Lobbying Activity
Political campaign activity
No
Lobbying activity
No
Subject to proxy tax
No
Governance and Compliance

Governance Checklist

Compiled or reviewed by an accountant
No
Annual disclosure for covered persons
No
Business relationship with family members
No
Business relationship with organization members
No
Material changes to governing documents
No
Compensation from other sources disclosed
No
CEO compensation reviewed
No
Other officer compensation reviewed
No
Conflict-of-interest policy
Yes
Audited financial statements prepared
No
Key decisions subject to board approval
No
Management duties delegated
No

Governance Explanations

Form 990, Part VI, Section A, Line 2

“The president of the foundation has immaterial ownership interest, in the investments of fortress and silver lake, which are managed by two of the directors.”

Form 990, Part VI, Section A, Line 7A

“The president of the foundation has authority to elect one or more members of the governing body.”

Form 990, Part VI, Section A, Line 8A

“The governing body of the foundation did not meet during the year.”

Form 990, Part VI, Section A, Line 8B

“The foundation does not have any committees.”

Form 990, Part VI, Section B, Line 11B

“Prior to filing from 990, the foundation's president will review the form.”

Form 990, Part VI, Section C, Line 18

“AVAILABLE UPON REQUEST.”

Form 990, Part VI, Section C, Line 19

“AVAILABLE UPON REQUEST.”

Filing and Contact Details

Filer

Filer Name
Grace Science Foundation
EIN
46-5727883
Phone
4152557666
Address
235 KANSAS STREET SUITE 200, SAN FRANCISCO, CA 94103

Signing Officer

Name
Matthew R Wilsey
Title
President
Phone
4152557666
Signed
2019-05-15
Discuss with paid preparer
Yes

Organization Details

Principal Officer
Matthew R Wilsey
Formed
2014
Legal Domicile
CA
Voting Board Members
7
Independent Board Members
7
Employees
0
Volunteers
10

Preparer

Firm
Oum & Co Llp
Address
601 CALIFORNIA STREET SUITE 1800, SAN FRANCISCO, CA 94108
Preparer
Bradford Weisert
Phone
4154343744
Raw XML AppendixShowing 400 of 475 raw XML fields

This appendix keeps the raw XML leaves available for debugging and edge-case review. The human report above is the primary experience.

Path#Value
IRS990/AccountantCompileOrReviewInd00
IRS990/ActivitiesConductedPrtshpInd00
IRS990/ActivityOrMissionDesc0THE MISSION OF THE FOUNDATION IS TO SUPPORT AND FUND THE DEVELOPMENT OF LIFE-SAVING TREATMENT FOR PATIENTS THAT ARE DEFICIENT IN THE N-GLYCANESE ENZYME AND THOSE SUFFERING FROM RELATED GENETIC DISEASES.
IRS990/AdvertisingGrp/ManagementAndGeneralAmt08760
IRS990/AdvertisingGrp/TotalAmt08760
IRS990/AllOtherContributionsAmt01187802
IRS990/AnnualDisclosureCoveredPrsnInd00
IRS990/BooksInCareOfDetail/BusinessName/BusinessNameLine1Txt0GRACE SCIENCE FOUNDATION
IRS990/BooksInCareOfDetail/PhoneNum04152557666
IRS990/BooksInCareOfDetail/USAddress/AddressLine1Txt0235 KANSAS STREET SUITE 200
IRS990/BooksInCareOfDetail/USAddress/CityNm0SAN FRANCISCO
IRS990/BooksInCareOfDetail/USAddress/StateAbbreviationCd0CA
IRS990/BooksInCareOfDetail/USAddress/ZIPCd094103
IRS990/BusinessRlnWithFamMemInd00
IRS990/BusinessRlnWithOfficerEntInd00
IRS990/BusinessRlnWithOrgMemInd00
IRS990/CapStkTrPrinCurrentFundsGrp/BOYAmt00
IRS990/CapStkTrPrinCurrentFundsGrp/EOYAmt00
IRS990/CashNonInterestBearingGrp/BOYAmt02109224
IRS990/CashNonInterestBearingGrp/EOYAmt02192300
IRS990/ChangeToOrgDocumentsInd00
IRS990/CntrctRcvdGreaterThan100KCnt00
IRS990/CollectionsOfArtInd00
IRS990/CompensationFromOtherSrcsInd00
IRS990/CompensationProcessCEOInd00
IRS990/CompensationProcessOtherInd00
IRS990/ConflictOfInterestPolicyInd01
IRS990/ConservationEasementsInd00
IRS990/ConsolidatedAuditFinclStmtInd00
IRS990/CreditCounselingInd00
IRS990/CYBenefitsPaidToMembersAmt00
IRS990/CYContributionsGrantsAmt01187802
IRS990/CYGrantsAndSimilarPaidAmt0898851
IRS990/CYInvestmentIncomeAmt012186
IRS990/CYOtherExpensesAmt0175213
IRS990/CYOtherRevenueAmt00
IRS990/CYProgramServiceRevenueAmt00
IRS990/CYRevenuesLessExpensesAmt0125924
IRS990/CYSalariesCompEmpBnftPaidAmt00
IRS990/CYTotalExpensesAmt01074064
IRS990/CYTotalFundraisingExpenseAmt00
IRS990/CYTotalProfFndrsngExpnsAmt00
IRS990/CYTotalRevenueAmt01199988
IRS990/DecisionsSubjectToApprovaInd00
IRS990/DeductibleArtContributionInd00
IRS990/DeductibleNonCashContriInd01
IRS990/DelegationOfMgmtDutiesInd00
IRS990/Desc0STANFORD UNIVERSITY (BERTOZZI LAB) - TEAM BEGAN INVESTIGATING A POSSIBLE ROLE FOR FERROPTOSIS AND OXIDATIVE STRESS IN THE PATHOLOGIES ASSOCIATED WITH NGLY1 DEFICIENCY. THESE FINDINGS TOUCH ON KNOWN PATHWAYS AND COULD THEREFORE INFORM POTENTIAL THERAPEUTIC STRATEGIES. ADDITIONALLY, THE TEAM MADE SIGNIFICANT PROGRESS ON A FLUOROGENIC PROBE TO DETECT NGLY1 ACTIVITY IN LIVE CELLS THAT DOES NOT REQUIRE THE CELLS TO BE GENETICALLY ENGINEERED. THE TEAM ALSO DEVELOPED A FIRST VERSION OF NGLY1-TURBOID, A SYSTEM DESIGNED TO IDENTIFY NGLY1 INTERACTORS AND POTENTIAL SUBSTRATES. THIS IS CRITICAL TO UNCOVERING PROTEINS INVOLVED IN NGLY1 FUNCTION AS WELL AS ADDITIONAL PROTEINS, LIKE NFE2L1, THAT NGLY1 MAY REGULATE THROUGH DEGLYCOSYLATION. SUCH PROTEINS COULD SERVE AS POTENTIAL TARGETS FOR A SMALL COMPOUND THERAPEUTIC AND COULD PROVIDE ESSENTIAL INSIGHT INTO NGLY1 BIOLOGY.
IRS990/DescribedInSection501c3Ind01
IRS990/DisregardedEntityInd00
IRS990/DocumentRetentionPolicyInd00
IRS990/DonorAdvisedFundInd00
IRS990/ElectionOfBoardMembersInd01
IRS990/EmployeeCnt00
IRS990/EngagedInExcessBenefitTransInd00
IRS990/ExpenseAmt0255345
IRS990/FamilyOrBusinessRlnInd01
IRS990/FederalGrantAuditRequiredInd00
IRS990/FeesForServicesAccountingGrp/ManagementAndGeneralAmt04275
IRS990/FeesForServicesAccountingGrp/TotalAmt04275
IRS990/FeesForServicesLegalGrp/ManagementAndGeneralAmt012413
IRS990/FeesForServicesLegalGrp/TotalAmt012413
IRS990/FeesForServicesOtherGrp/ManagementAndGeneralAmt081250
IRS990/FeesForServicesOtherGrp/TotalAmt081250
IRS990/ForeignActivitiesInd00
IRS990/ForeignFinancialAccountInd00
IRS990/ForeignGrantsGrp/ProgramServicesAmt037500
IRS990/ForeignGrantsGrp/TotalAmt037500
IRS990/ForeignOfficeInd00
IRS990/Form8282PropertyDisposedOfInd00
IRS990/Form990PartVIISectionAGrp/AverageHoursPerWeekRt020.00
IRS990/Form990PartVIISectionAGrp/AverageHoursPerWeekRt11.00
IRS990/Form990PartVIISectionAGrp/AverageHoursPerWeekRt21.00
IRS990/Form990PartVIISectionAGrp/AverageHoursPerWeekRt31.00
IRS990/Form990PartVIISectionAGrp/AverageHoursPerWeekRt41.00
IRS990/Form990PartVIISectionAGrp/AverageHoursPerWeekRt51.00
IRS990/Form990PartVIISectionAGrp/AverageHoursPerWeekRt61.00
IRS990/Form990PartVIISectionAGrp/IndividualTrusteeOrDirectorInd0X
IRS990/Form990PartVIISectionAGrp/IndividualTrusteeOrDirectorInd1X
IRS990/Form990PartVIISectionAGrp/IndividualTrusteeOrDirectorInd2X
IRS990/Form990PartVIISectionAGrp/IndividualTrusteeOrDirectorInd3X
IRS990/Form990PartVIISectionAGrp/IndividualTrusteeOrDirectorInd4X
IRS990/Form990PartVIISectionAGrp/IndividualTrusteeOrDirectorInd5X
IRS990/Form990PartVIISectionAGrp/IndividualTrusteeOrDirectorInd6X
IRS990/Form990PartVIISectionAGrp/OfficerInd0X
IRS990/Form990PartVIISectionAGrp/OfficerInd1X
IRS990/Form990PartVIISectionAGrp/OfficerInd2X
IRS990/Form990PartVIISectionAGrp/OtherCompensationAmt00
IRS990/Form990PartVIISectionAGrp/OtherCompensationAmt10
IRS990/Form990PartVIISectionAGrp/OtherCompensationAmt20
IRS990/Form990PartVIISectionAGrp/OtherCompensationAmt30
IRS990/Form990PartVIISectionAGrp/OtherCompensationAmt40
IRS990/Form990PartVIISectionAGrp/OtherCompensationAmt50
IRS990/Form990PartVIISectionAGrp/OtherCompensationAmt60
IRS990/Form990PartVIISectionAGrp/PersonNm0MATTHEW WILSEY
IRS990/Form990PartVIISectionAGrp/PersonNm1EGON DURBAN
IRS990/Form990PartVIISectionAGrp/PersonNm2KEN DRAZAN
IRS990/Form990PartVIISectionAGrp/PersonNm3PETE BRIGER
IRS990/Form990PartVIISectionAGrp/PersonNm4CHELSEA CLINTON
IRS990/Form990PartVIISectionAGrp/PersonNm5J TAYLOR CRANDALL
IRS990/Form990PartVIISectionAGrp/PersonNm6ELLE STEPHENS
IRS990/Form990PartVIISectionAGrp/ReportableCompFromOrgAmt00
IRS990/Form990PartVIISectionAGrp/ReportableCompFromOrgAmt10
IRS990/Form990PartVIISectionAGrp/ReportableCompFromOrgAmt20
IRS990/Form990PartVIISectionAGrp/ReportableCompFromOrgAmt30
IRS990/Form990PartVIISectionAGrp/ReportableCompFromOrgAmt40
IRS990/Form990PartVIISectionAGrp/ReportableCompFromOrgAmt50
IRS990/Form990PartVIISectionAGrp/ReportableCompFromOrgAmt60
IRS990/Form990PartVIISectionAGrp/ReportableCompFromRltdOrgAmt00
IRS990/Form990PartVIISectionAGrp/ReportableCompFromRltdOrgAmt10
IRS990/Form990PartVIISectionAGrp/ReportableCompFromRltdOrgAmt20
IRS990/Form990PartVIISectionAGrp/ReportableCompFromRltdOrgAmt30
IRS990/Form990PartVIISectionAGrp/ReportableCompFromRltdOrgAmt40
IRS990/Form990PartVIISectionAGrp/ReportableCompFromRltdOrgAmt50
IRS990/Form990PartVIISectionAGrp/ReportableCompFromRltdOrgAmt60
IRS990/Form990PartVIISectionAGrp/TitleTxt0PRESIDENT
IRS990/Form990PartVIISectionAGrp/TitleTxt1CHIEF FINANCIAL OFFICER
IRS990/Form990PartVIISectionAGrp/TitleTxt2SECRETARY
IRS990/Form990PartVIISectionAGrp/TitleTxt3DIRECTOR
IRS990/Form990PartVIISectionAGrp/TitleTxt4DIRECTOR
IRS990/Form990PartVIISectionAGrp/TitleTxt5DIRECTOR
IRS990/Form990PartVIISectionAGrp/TitleTxt6DIRECTOR
IRS990/Form990ProvidedToGvrnBodyInd00
IRS990/FormationYr02014
IRS990/FormerOfcrEmployeesListedInd00
IRS990/FSAuditedInd00
IRS990/FundraisingActivitiesInd00
IRS990/GainOrLossGrp/SecuritiesAmt06361
IRS990/GamingActivitiesInd00
IRS990/GoverningBodyVotingMembersCnt07
IRS990/GrantAmt0250000
IRS990/GrantsPayableGrp/BOYAmt016500
IRS990/GrantsPayableGrp/EOYAmt00
IRS990/GrantsToDomesticOrgsGrp/ProgramServicesAmt0861351
IRS990/GrantsToDomesticOrgsGrp/TotalAmt0861351
IRS990/GrantsToIndividualsInd00
IRS990/GrantsToOrganizationsInd01
IRS990/GrantToRelatedPersonInd00
IRS990/GrossAmountSalesAssetsGrp/SecuritiesAmt010451
IRS990/GrossReceiptsAmt01204078
IRS990/GroupReturnForAffiliatesInd00
IRS990/IncludeFIN48FootnoteInd00
IRS990/IndependentAuditFinclStmtInd00
IRS990/IndependentVotingMemberCnt07
IRS990/IndivRcvdGreaterThan100KCnt00
IRS990/IndoorTanningServicesInd00
IRS990/InfoInScheduleOPartIIIInd0X
IRS990/InfoInScheduleOPartVIInd0X
IRS990/InsuranceGrp/ManagementAndGeneralAmt0955
IRS990/InsuranceGrp/TotalAmt0955
IRS990/InvestmentIncomeGrp/ExclusionAmt05825
IRS990/InvestmentIncomeGrp/TotalRevenueColumnAmt05825
IRS990/InvestmentInJointVentureInd00
IRS990/InvestmentsPubTradedSecGrp/EOYAmt04074
IRS990/IRPDocumentCnt05
IRS990/IRPDocumentW2GCnt00
IRS990/LegalDomicileStateCd0CA
IRS990/LessCostOthBasisSalesExpnssGrp/SecuritiesAmt04090
IRS990/LoanOutstandingInd00
IRS990/LobbyingActivitiesInd00
IRS990/LocalChaptersInd00
IRS990/MaterialDiversionOrMisuseInd00
IRS990/MembersOrStockholdersInd00
IRS990/MethodOfAccountingCashInd0X
IRS990/MinutesOfCommitteesInd00
IRS990/MinutesOfGoverningBodyInd00
IRS990/MissionDesc0THE MISSION OF THE FOUNDATION IS TO SUPPORT AND FUND THE DEVELOPMENT OF LIFE-SAVING TREATMENT FOR PATIENTS THAT ARE DEFICIENT IN THE N-GLYCANESE ENZYME AND THOSE SUFFERING FROM RELATED GENETIC DISEASES. THE ACTIVITIES OF THE FOUNDATION WILL INVOLVE PROVIDING GRANT FUNDING TO HOSPITALS AND MEDICAL RESEARCH FACILITIES WHICH ARE CONDUCTING MEDICAL RESEARCH IN VARIOUS FIELDS RELATING TO THE SEARCH FOR UNDERSTANDING AND TREATMENT OF THIS CONDITION, AND FOSTERING COLLABORATION BETWEEN ACADEMIA, RESEARCH INSTITUTIONS, HOSPITALS, PRIVATE COMPANIES, AND GOVERNMENTAL AGENCIES.
IRS990/MoreThan5000KToIndividualsInd00
IRS990/MoreThan5000KToOrgInd01
IRS990/NetAssetsOrFundBalancesBOYAmt02092724
IRS990/NetAssetsOrFundBalancesEOYAmt02196374
IRS990/NetGainOrLossInvestmentsGrp/ExclusionAmt06361
IRS990/NetGainOrLossInvestmentsGrp/TotalRevenueColumnAmt06361
IRS990/NetUnrelatedBusTxblIncmAmt00
IRS990/NetUnrlzdGainsLossesInvstAmt0-22274
IRS990/NoListedPersonsCompensatedInd0X
IRS990/NoncashContributionsAmt030437
IRS990/NondeductibleContributionsInd00
IRS990/OfficeExpensesGrp/ManagementAndGeneralAmt011225
IRS990/OfficeExpensesGrp/ProgramServicesAmt0861
IRS990/OfficeExpensesGrp/TotalAmt012086
IRS990/OfficerMailingAddressInd00
IRS990/OperateHospitalInd00
IRS990/Organization501c3Ind0X
IRS990/OrgDoesNotFollowSFAS117Ind0X
IRS990/OtherChangesInNetAssetsAmt00
IRS990/OtherExpensesGrp/Desc0BRANDING/LOGO/VIDEO/WEB
IRS990/OtherExpensesGrp/Desc1OTHER FEES (BANK, CREDI
IRS990/OtherExpensesGrp/Desc2FILING FEES
IRS990/OtherExpensesGrp/ManagementAndGeneralAmt013150
IRS990/OtherExpensesGrp/ManagementAndGeneralAmt1173
IRS990/OtherExpensesGrp/ManagementAndGeneralAmt2160
IRS990/OtherExpensesGrp/TotalAmt013150
IRS990/OtherExpensesGrp/TotalAmt1173
IRS990/OtherExpensesGrp/TotalAmt2160
IRS990/OtherWebsiteInd0X
IRS990/PartialLiquidationInd00
IRS990/PdInCapSrplsLandBldgEqpFundGrp/BOYAmt00
IRS990/PdInCapSrplsLandBldgEqpFundGrp/EOYAmt00
IRS990/PoliticalCampaignActyInd00
IRS990/PrincipalOfficerNm0MATTHEW R WILSEY
IRS990/ProfessionalFundraisingInd00
IRS990/ProgSrvcAccomActy2Grp/Desc0SALK INSTITUTE FOR BIOLOICAL SCIENCES (GAGE LAB) - TEAM GENERATED NEURONS FROM THE INDUCED PLURIPOTENT STEM CELLS (IPSCS) OF NGLY1 DEFICIENT PATIENTS TO CHARACTERIZE THEIR FUNCTIONAL CHANGES COMPARED WITH CONTROL SAMPLES. THEY DISCOVERED NEURITIC BEADING IN PATIENT NEURONS, A HALLMARK OF NEURONAL TOXICITY IN SEVERAL PATHOGENIC CONDITIONS. THEY ALSO OBSERVED THE PRESENCE OF PROTEIN AGGREGATES AND REDUCED SYNAPTIC ACTIVITY IN PATIENT CELLS COMPARED WITH CONTROLS. IN ADDITION TO NEURONS, THE TEAM ALSO DERIVED GLIAL PROGENITOR CELLS (GPCS) FROM IPSCS AND DID NOT OBSERVE THE FUNCTIONAL DEFECTS IN PRIMARY ASTROCYTES AS FOUND IN NEURONS. THESE DISCOVERIES IDENTIFIED PHENOTYPES THAT CAN BE LEVERAGED FOR HIGH-THROUGHPUT DRUG SCREENS AND PROVIDE INSIGHT AS TO THE CELL TYPES AFFECTED BY THE DISEASE IN PATIENTS.
IRS990/ProgSrvcAccomActy2Grp/ExpenseAmt0170966
IRS990/ProgSrvcAccomActy2Grp/GrantAmt0165621
IRS990/ProgSrvcAccomActy3Grp/Desc0MASSACHUSETTS GENERAL HOSPITAL (RUVKUN LAB) - TEAM CONTINUED THEIR ANALYSIS OF THE GENETIC MODIFIERS OF PROTEASOME DYSFUNCTION THEY PREVIOUSLY IDENTIFIED IN PNG-1 / NGLY1 DEFICIENT C. ELEGANS. THIS LED TO THE IDENTIFICATION OF A SPECIFIC PATHWAY WHOSE DISRUPTION APPEARS BENEFICIAL TO PROTEASOME DYSFUNCTION IN NGLY1 DEFICIENT ANIMALS, A FINDING THAT COULD TRANSLATE INTO A POTENTIAL THERAPY FOR THE DISEASE IN HUMANS. THEY ALSO DEMONSTRATED NGLY1 UNIQUELY ALLOWS EDITING OF THE UNDERLYING CODING SEQUENCE OF A GENE AT THE POST-TRANSLATIONAL LEVEL TO INFLUENCE THE ACTIVITY OF ONE OF ITS SUBSTRATES, THE KEY TRANSCRIPTIONAL REGULATOR SKN-1A / NFE2L1. ADDITIONALLY, THE TEAM DEMONSTRATED THAT SKN-1A/NFE2L1 IS ACTIVATED BY MISFOLDED PROTEINS, A FINDING WITH POTENTIAL RELEVANCE TO NEURODEGENERATIVE DISEASES. COLLECTIVELY, THESE RESULTS WERE SUBMITTED TO TWO SEPARATE, INFLUENTIAL JOURNALS.
IRS990/ProgSrvcAccomActy3Grp/ExpenseAmt0128395
IRS990/ProgSrvcAccomActy3Grp/GrantAmt0123050
IRS990/ProgSrvcAccomActyOtherGrp/Desc0UNIVERSITY OF TEXAS SOUTHWESTERN (YAN LAB) - TEAM TESTED SEVERAL COMPOUNDS THAT ARE KNOWN TO ACTIVATE A SPECIFIC PROTEIN INVOLVED IN THE RESPONSE TO OXIDATIVE STRESS FOR RESCUE OF DEFECTS IN NGLY1 DEFICIENT CELLS. THEY FOUND SULFORAPHANE (SFN) COULD SUBSTANTIALLY RESCUE INNATE IMMUNE SIGNALING AND MITOPHAGY DEFECTS AND IMPROVE MITOCHONDRIAL MORPHOLOGY AND HOMEOSTASIS. SFN TREATMENT OF PREGNANT NGLY1 -/- MICE ALSO SHOWED PARTIAL RESCUE OF EMBRYONIC LETHALITY, PROVIDING A PRECLINICAL STUDY OF THE DRUG IN MICE. THROUGH A GENETIC APPROACH, THE TEAM GENERATED EVIDENCE THAT NGLY1 DEFICIENCY TRIGGERS THE STING-DEPENDENT INNATE IMMUNE SENSING PATHWAY IN MOUSE EMBRYONIC STEM CELLS. THE TEAM ALSO GENERATED A TAMOXIFEN INDUCIBLE NGLY1 KO MOUSE MODEL THAT CAN BE USED FOR A VARIETY OF PURPOSE, FOR INSTANCE THE STUDY OF DISEASE PHENOTYPES, BIOMARKER EVALUATION, AND GENE THERAPY PROOF OF CONCEPT EXPERIMENTS.
IRS990/ProgSrvcAccomActyOtherGrp/Desc1UNIVERSITY OF MASSACHUSETTS MEDICAL SCHOOL (GAO LAB) - TEAM CONSTRUCTED THREE DIFFERENT RAAV VECTORS CONTAINING THE HUMAN NGLY1 (HNGLY1) TRANSGENE FOR CHARACTERIZATION OF THEIR DELIVERY AND EXPRESSION IN MICE TO UNDERSTAND THE EFFECTS OF OVEREXPRESSING HNGLY1 AND EVALUATE THE SAFETY OF DELIVERING HNGLY1 USING RAAV. THEY QUANTIFIED THE PRESENCE OF THE RAAV VECTOR GENOME AND HNGLY1 IN THE VARIOUS MOUSE TISSUES (INCLUDING LIVER, HIPPOCAMPUS, CORTEX, AND CEREBELLUM) AND DID NOT OBSERVE ANY DELETERIOUS EFFECTS ON THE MICE. THESE EXPERIMENTS ARE IMPORTANT PROOF OF CONCEPT EXPERIMENTS FOR AN NGLY1 GENE THERAPY APPROACH AS THEY DEMONSTRATED SUCCESSFULLY DELIVERY OF HNGLY1 USING DIFFERENT CONFIGURATIONS OF A RAAV VECTOR AND A LACK OF TOXICITY TO THE ANIMAL.
IRS990/ProgSrvcAccomActyOtherGrp/Desc2THE JACKSON LABORATORY (CAT LUTZ) - THE TEAM GENERATED A TRANSGENIC MOUSE EXPRESSING HUMAN NGLY1 IN A CONDITIONAL CRE-DEPENDENT MANNER, SHOWING IT COULD RESCUE THE MOUSE EMBRYONIC LETHALITY PHENOTYPE OF AN NGLY1 DEFICIENT MOUSE MODEL. THEY ALSO DEMONSTRATED A DOUBLE NGLY -/- / ENGASE -/- KNOCKOUT IS PARTIALLY VIABLE FOR A CERTAIN ALLELE OF NGLY1 AND BEGAN DEEP PHENOTYPIC ANALYSIS OF THESE MICE TO DETERMINE WHETHER THEY EXHIBIT ANY PATHOLOGIES. IF SO, THESE MICE COULD BE A USEFUL MODEL FOR TESTING POTENTIAL THERAPIES THAT COULD REVERSE PATHOLOGIES ASSOCIATED WITH NGLY1 DEFICIENCY (SINCE THE SINGLE KNOCKOUT MOUSE IS EMBRYONIC LETHAL). LASTLY, THE TEAM GENERATED SEVERAL TISSUE-SPECIFIC CONDITIONAL KNOCK-IN CLINICAL ALLELES OF NGLY1 TO HELP UNDERSTAND WHICH TISSUES ARE IMPORTANT IN THE DISEASE PATHOLOGY.
IRS990/ProgSrvcAccomActyOtherGrp/Desc3OTHER PROGRAM SERVICES ARE RELATED TO RESEARCH AND DEVELOPMENT TO UNDERSTAND AND CURE CARE DISEASES BEGINNING WITH NGLY1 DEFICIENCY.
IRS990/ProgSrvcAccomActyOtherGrp/ExpenseAmt0113085
IRS990/ProgSrvcAccomActyOtherGrp/ExpenseAmt165345
IRS990/ProgSrvcAccomActyOtherGrp/ExpenseAmt255345
IRS990/ProgSrvcAccomActyOtherGrp/ExpenseAmt3147783
IRS990/ProgSrvcAccomActyOtherGrp/GrantAmt0107740
IRS990/ProgSrvcAccomActyOtherGrp/GrantAmt160000
IRS990/ProgSrvcAccomActyOtherGrp/GrantAmt250000
IRS990/ProgSrvcAccomActyOtherGrp/GrantAmt3142440
IRS990/ProhibitedTaxShelterTransInd00
IRS990/PYBenefitsPaidToMembersAmt00
IRS990/PYContributionsGrantsAmt01651481
IRS990/PYExcessBenefitTransInd00
IRS990/PYGrantsAndSimilarPaidAmt0696567
IRS990/PYInvestmentIncomeAmt00
IRS990/PYOtherExpensesAmt0223947
IRS990/PYOtherRevenueAmt025626
IRS990/PYProgramServiceRevenueAmt00
IRS990/PYRevenuesLessExpensesAmt0756593
IRS990/PYSalariesCompEmpBnftPaidAmt00
IRS990/PYTotalExpensesAmt0920514
IRS990/PYTotalProfFndrsngExpnsAmt00
IRS990/PYTotalRevenueAmt01677107
IRS990/QuidProQuoContributionsInd00
IRS990/ReconcilationRevenueExpnssAmt0125924
IRS990/RegularMonitoringEnfrcInd00
IRS990/RelatedEntityInd00
IRS990/RelatedOrganizationCtrlEntInd00
IRS990/ReportInvestmentsOtherSecInd00
IRS990/ReportLandBuildingEquipmentInd00
IRS990/ReportOtherAssetsInd00
IRS990/ReportOtherLiabilitiesInd00
IRS990/ReportProgramRelatedInvstInd00
IRS990/RtnEarnEndowmentIncmOthFndsGrp/BOYAmt02092724
IRS990/RtnEarnEndowmentIncmOthFndsGrp/EOYAmt02196374
IRS990ScheduleA/First5Years170Ind0X
IRS990ScheduleA/Form990ScheduleAPartVIGrp/ExplanationTxt0GRACE SCIENCE FOUNDATION WAS FORMED ON MAY 19, 2014. 2018 IS THE FOUNDATION'S FIFTH YEAR OF EXISTENCE.
IRS990ScheduleA/Form990ScheduleAPartVIGrp/FormAndLineReferenceDesc0PART II AND LINE 13
IRS990ScheduleA/GiftsGrantsContriRcvd170Grp/CurrentTaxYearAmt01157365
IRS990ScheduleA/GiftsGrantsContriRcvd170Grp/CurrentTaxYearMinus1YearAmt01677107
IRS990ScheduleA/GiftsGrantsContriRcvd170Grp/CurrentTaxYearMinus2YearsAmt0600124
IRS990ScheduleA/GiftsGrantsContriRcvd170Grp/CurrentTaxYearMinus3YearsAmt01560381
IRS990ScheduleA/GiftsGrantsContriRcvd170Grp/CurrentTaxYearMinus4YearsAmt0664490
IRS990ScheduleA/GiftsGrantsContriRcvd170Grp/TotalAmt05659467
IRS990ScheduleA/PublicOrganization170Ind0X
IRS990ScheduleA/PublicSupportTotal170Amt03899034
IRS990ScheduleA/SubstantialContributorsTotAmt01760433
IRS990ScheduleA/TotalCalendarYear170Grp/CurrentTaxYearAmt01157365
IRS990ScheduleA/TotalCalendarYear170Grp/CurrentTaxYearMinus1YearAmt01677107
IRS990ScheduleA/TotalCalendarYear170Grp/CurrentTaxYearMinus2YearsAmt0600124
IRS990ScheduleA/TotalCalendarYear170Grp/CurrentTaxYearMinus3YearsAmt01560381
IRS990ScheduleA/TotalCalendarYear170Grp/CurrentTaxYearMinus4YearsAmt0664490
IRS990ScheduleA/TotalCalendarYear170Grp/TotalAmt05659467
IRS990ScheduleA/TotalSupportAmt05659467
IRS990/ScheduleBRequiredInd01
IRS990ScheduleF/BoycottCountriesInd00
IRS990ScheduleF/ContinuationSpentAmt00
IRS990ScheduleF/ContinuationTotalEmployeeCnt00
IRS990ScheduleF/ContinuationTotalOfficeCnt00
IRS990ScheduleF/ForeignCorpOwnershipInd00
IRS990ScheduleF/ForeignPartnershipInd00
IRS990ScheduleF/GrantsToOrgOutsideUSGrp/CashGrantAmt037500
IRS990ScheduleF/GrantsToOrgOutsideUSGrp/MannerOfCashDisbursementTxt0CHECK
IRS990ScheduleF/GrantsToOrgOutsideUSGrp/PurposeOfGrantTxt0NGYL1 WORK IN MOFFAT'S LABS AT UNIVERSITY OF TORONTO
IRS990ScheduleF/GrantsToOrgOutsideUSGrp/RegionTxt0CANADA
IRS990ScheduleF/InterestInForeignTrustInd00
IRS990ScheduleF/PassiveForeignInvestmestCoInd00
IRS990ScheduleF/SubtotalEmployeesCnt00
IRS990ScheduleF/SubtotalOfficesCnt00
IRS990ScheduleF/SubtotalSpentAmt00
IRS990ScheduleF/Total501c3OrgCnt01
IRS990ScheduleF/TotalEmployeeCnt00
IRS990ScheduleF/TotalOfficeCnt00
IRS990ScheduleF/TotalSpentAmt00
IRS990ScheduleF/TransferToForeignCorpInd00
IRS990ScheduleI/GrantRecordsMaintainedInd01
IRS990ScheduleI/RecipientTable/CashGrantAmt0100000
IRS990ScheduleI/RecipientTable/CashGrantAmt1268187
IRS990ScheduleI/RecipientTable/CashGrantAmt239050
IRS990ScheduleI/RecipientTable/CashGrantAmt3178158
IRS990ScheduleI/RecipientTable/CashGrantAmt4124215
IRS990ScheduleI/RecipientTable/CashGrantAmt550000
IRS990ScheduleI/RecipientTable/CashGrantAmt630000
IRS990ScheduleI/RecipientTable/CashGrantAmt771741
IRS990ScheduleI/RecipientTable/IRCSectionDesc0501(C)(3)
IRS990ScheduleI/RecipientTable/IRCSectionDesc1501(C)(3)
IRS990ScheduleI/RecipientTable/IRCSectionDesc2501(C)(3)
IRS990ScheduleI/RecipientTable/IRCSectionDesc3501(C)(3)
IRS990ScheduleI/RecipientTable/IRCSectionDesc4501(C)(3)
IRS990ScheduleI/RecipientTable/IRCSectionDesc5501(C)(6)
IRS990ScheduleI/RecipientTable/IRCSectionDesc6501(C)(6)
IRS990ScheduleI/RecipientTable/PurposeOfGrantTxt0ASSAY DEVELOPMENT & COMPOUND SCREENING
IRS990ScheduleI/RecipientTable/PurposeOfGrantTxt1NGLY1 WORK IN BERTOZZI/SNYDER/STEINMETZ LABS & NATURAL HISTORY PROTOCOL DEVELOPMENT
IRS990ScheduleI/RecipientTable/PurposeOfGrantTxt2CMAP STUDY & GENETIC SEQUENCING
IRS990ScheduleI/RecipientTable/PurposeOfGrantTxt3NGLY1 WORK IN JAFAR-NEJAD LAB
IRS990ScheduleI/RecipientTable/PurposeOfGrantTxt4NGLY1 WORK IN GAGE LAB
IRS990ScheduleI/RecipientTable/PurposeOfGrantTxt5NGLY1 WORK WITH CAT LUTZ
IRS990ScheduleI/RecipientTable/PurposeOfGrantTxt6NGLY1 WORK IN GAO LAB
IRS990ScheduleI/RecipientTable/PurposeOfGrantTxt7NGLY1 WORK IN YAN LAB
IRS990ScheduleI/RecipientTable/RecipientBusinessName/BusinessNameLine1Txt0PERLARA PBC
IRS990ScheduleI/RecipientTable/RecipientBusinessName/BusinessNameLine1Txt1STANFORD UNIVERSITY
IRS990ScheduleI/RecipientTable/RecipientBusinessName/BusinessNameLine1Txt2BROAD INSTITUTE
IRS990ScheduleI/RecipientTable/RecipientBusinessName/BusinessNameLine1Txt3BAYLOR COLLEGE OF MEDICINE
IRS990ScheduleI/RecipientTable/RecipientBusinessName/BusinessNameLine1Txt4SALK INSTITUTE FOR BIOLOGICAL STUDIES
IRS990ScheduleI/RecipientTable/RecipientBusinessName/BusinessNameLine1Txt5THE JACKSON LABORATORY
IRS990ScheduleI/RecipientTable/RecipientBusinessName/BusinessNameLine1Txt6UNIVERSITY OF MASSACHUSETTS MEDICAL SCHOOL
IRS990ScheduleI/RecipientTable/RecipientBusinessName/BusinessNameLine1Txt7UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER
IRS990ScheduleI/RecipientTable/RecipientEIN0941156365
IRS990ScheduleI/RecipientTable/RecipientEIN1263428781
IRS990ScheduleI/RecipientTable/RecipientEIN2741613878
IRS990ScheduleI/RecipientTable/RecipientEIN3952160097
IRS990ScheduleI/RecipientTable/RecipientEIN4010211513
IRS990ScheduleI/RecipientTable/RecipientEIN5043167352
IRS990ScheduleI/RecipientTable/RecipientEIN6756002868
IRS990ScheduleI/RecipientTable/USAddress/AddressLine1Txt06000 SHORELINE CT SUITE 204
IRS990ScheduleI/RecipientTable/USAddress/AddressLine1Txt13145 PORTER DRIVE
IRS990ScheduleI/RecipientTable/USAddress/AddressLine1Txt2415 MAIN STREET
IRS990ScheduleI/RecipientTable/USAddress/AddressLine1Txt31102 BATES AVENUE SUITE 48002
IRS990ScheduleI/RecipientTable/USAddress/AddressLine1Txt410010 N TORREY PINES ROAD
IRS990ScheduleI/RecipientTable/USAddress/AddressLine1Txt5600 MAIN STREET
IRS990ScheduleI/RecipientTable/USAddress/AddressLine1Txt655 LAKE AVENUE NORTH
IRS990ScheduleI/RecipientTable/USAddress/AddressLine1Txt75323 HARRY HINES BLVD
IRS990ScheduleI/RecipientTable/USAddress/CityNm0S SAN FRANCISCO
IRS990ScheduleI/RecipientTable/USAddress/CityNm1PALO ALTO
IRS990ScheduleI/RecipientTable/USAddress/CityNm2CAMBRIDGE
IRS990ScheduleI/RecipientTable/USAddress/CityNm3HOUSTON
IRS990ScheduleI/RecipientTable/USAddress/CityNm4LA JOLLA
IRS990ScheduleI/RecipientTable/USAddress/CityNm5BAR HARBOR
IRS990ScheduleI/RecipientTable/USAddress/CityNm6WORCESTER
IRS990ScheduleI/RecipientTable/USAddress/CityNm7DALLAS
IRS990ScheduleI/RecipientTable/USAddress/StateAbbreviationCd0CA
IRS990ScheduleI/RecipientTable/USAddress/StateAbbreviationCd1CA
IRS990ScheduleI/RecipientTable/USAddress/StateAbbreviationCd2MA
IRS990ScheduleI/RecipientTable/USAddress/StateAbbreviationCd3TX
IRS990ScheduleI/RecipientTable/USAddress/StateAbbreviationCd4CA
IRS990ScheduleI/RecipientTable/USAddress/StateAbbreviationCd5ME
IRS990ScheduleI/RecipientTable/USAddress/StateAbbreviationCd6MA
IRS990ScheduleI/RecipientTable/USAddress/StateAbbreviationCd7TX
IRS990ScheduleI/RecipientTable/USAddress/ZIPCd094080
IRS990ScheduleI/RecipientTable/USAddress/ZIPCd194304
IRS990ScheduleI/RecipientTable/USAddress/ZIPCd202142
IRS990ScheduleI/RecipientTable/USAddress/ZIPCd377030
IRS990ScheduleI/RecipientTable/USAddress/ZIPCd492037
IRS990ScheduleI/RecipientTable/USAddress/ZIPCd504609
IRS990ScheduleI/RecipientTable/USAddress/ZIPCd601655
IRS990ScheduleI/RecipientTable/USAddress/ZIPCd775390
IRS990ScheduleI/SupplementalInformationDetail/ExplanationTxt0* BEFORE FUNDING A PRINCIPAL INVESTIGATOR, THE FOUNDATION REQUIRES A DETAILED PROPOSAL WITH OBJECTIVES AND MILESTONES * THE PROPOSALS ARE REVIEWED BY THE FOUNDATION AND SCIENTIFIC ADVISORY BOARD * THE PROPOSALS ARE OFTEN REVISED SEVERAL TIMES TO GET THE CORRECT FIT * ONCE FUNDED, EACH PRINCIPAL INVESTIGATOR SUBMITS A WRITTEN SUMMARY EVERY QUARTER * THIS UPDATE IS TWO TO THREE PAGES IN LENGTH * THE REPORTS DISCUSS PROGRESS, HIGHLIGHT ROADBLOCKS AND IDENTIFY WHERE THEY NEED HELP * THE FOUNDATION STEPS-IN WHERE APPROPRIATE TO MAKE SURE OBJECTIVES AND MILESTONES ARE MET * IN ADDITION TO QUARTERLY REPORTS, THE FOUNDATION HOLDS A MONTHLY CONFERENCE CALL WHERE TWO TO THREE PRINCIPAL INVESTIGATORS PRESENT THEIR LATEST WORK * BEYOND THE ABOVE TWO INITIATIVES, THE FOUNDATION HOLDS ONE TO TWO IN-PERSON MEETINGS PER YEAR * DR. KEVIN LEE (CHIEF SCIENTIFIC OFFICER), DR. SELINA DWIGHT (PROGRAM MANAGER), AND MATT WILSEY(PRESIDENT) CONTACT RESEARCHERS AND PRINCIPAL INVESTIGATORS ON A REGULAR BASIS VIA EMAIL, PHONE, OR ONE ON ONE MEETINGS THE PRESIDENT ENSURES THAT EVERY DOLLAR IS USED TO SUPPORT THE GRACE SCIENCE FOUNDATION'S MISSION.
IRS990ScheduleI/SupplementalInformationDetail/FormAndLineReferenceDesc0PART I, LINE 2:
IRS990ScheduleI/Total501c3OrgCnt07
IRS990ScheduleI/TotalOtherOrgCnt01
IRS990/ScheduleJRequiredInd00
IRS990ScheduleM/AnyPropertyThatMustBeHeldInd00
IRS990ScheduleM/ReviewProcessUnusualNCGiftsInd00
IRS990ScheduleM/SecuritiesPubliclyTradedGrp/ContributionCnt03
IRS990ScheduleM/SecuritiesPubliclyTradedGrp/MethodOfDeterminingRevenuesTxt0FAIR MARKET VALUE
IRS990ScheduleM/SecuritiesPubliclyTradedGrp/NonCashCheckboxInd0X
IRS990ScheduleM/SecuritiesPubliclyTradedGrp/NoncashContributionsRptF990Amt030437
IRS990ScheduleM/ThirdPartiesUsedInd00
IRS990/ScheduleORequiredInd01
IRS990ScheduleO/SupplementalInformationDetail/ExplanationTxt0THE PRESIDENT OF THE FOUNDATION HAS IMMATERIAL OWNERSHIP INTEREST, IN THE INVESTMENTS OF FORTRESS AND SILVER LAKE, WHICH ARE MANAGED BY TWO OF THE DIRECTORS.
IRS990ScheduleO/SupplementalInformationDetail/ExplanationTxt1THE PRESIDENT OF THE FOUNDATION HAS AUTHORITY TO ELECT ONE OR MORE MEMBERS OF THE GOVERNING BODY.
IRS990ScheduleO/SupplementalInformationDetail/ExplanationTxt2THE GOVERNING BODY OF THE FOUNDATION DID NOT MEET DURING THE YEAR.
IRS990ScheduleO/SupplementalInformationDetail/ExplanationTxt3THE FOUNDATION DOES NOT HAVE ANY COMMITTEES.
IRS990ScheduleO/SupplementalInformationDetail/ExplanationTxt4PRIOR TO FILING FROM 990, THE FOUNDATION'S PRESIDENT WILL REVIEW THE FORM.
IRS990ScheduleO/SupplementalInformationDetail/ExplanationTxt5AVAILABLE UPON REQUEST.
IRS990ScheduleO/SupplementalInformationDetail/ExplanationTxt6AVAILABLE UPON REQUEST.
IRS990ScheduleO/SupplementalInformationDetail/FormAndLineReferenceDesc0FORM 990, PART VI, SECTION A, LINE 2
IRS990ScheduleO/SupplementalInformationDetail/FormAndLineReferenceDesc1FORM 990, PART VI, SECTION A, LINE 7A
IRS990ScheduleO/SupplementalInformationDetail/FormAndLineReferenceDesc2FORM 990, PART VI, SECTION A, LINE 8A
IRS990ScheduleO/SupplementalInformationDetail/FormAndLineReferenceDesc3FORM 990, PART VI, SECTION A, LINE 8B
IRS990ScheduleO/SupplementalInformationDetail/FormAndLineReferenceDesc4FORM 990, PART VI, SECTION B, LINE 11B
IRS990ScheduleO/SupplementalInformationDetail/FormAndLineReferenceDesc5FORM 990, PART VI, SECTION C, LINE 18
IRS990ScheduleO/SupplementalInformationDetail/FormAndLineReferenceDesc6FORM 990, PART VI, SECTION C, LINE 19
IRS990/SchoolOperatingInd00
IRS990/SignificantChangeInd00
IRS990/SignificantNewProgramSrvcInd00
IRS990/StatesWhereCopyOfReturnIsFldCd0CA
IRS990/SubjectToExcsTaxNetInvstIncInd00
IRS990/SubjectToProxyTaxInd00
IRS990/SubjToTaxRmnrtnExPrchtPymtInd00
IRS990/TaxablePartyNotificationInd00
IRS990/TaxExemptBondsInd00
IRS990/TempOrPermanentEndowmentsInd00
IRS990/TerminateOperationsInd00
IRS990/TotalAssetsBOYAmt02109224
IRS990/TotalAssetsEOYAmt02196374
IRS990/TotalAssetsGrp/BOYAmt02109224
IRS990/TotalAssetsGrp/EOYAmt02196374
IRS990/TotalCompGreaterThan150KInd00

Document Assets

No mirrored PDF or thumbnail assets are attached yet.

Filings

Displayed year

2018 • Form 990Detailed filing. Detailed filing data is available for this year.

Open filing
Assets
$2,196,374
Liabilities
$0
Net assets
$2,196,374
Revenue
$1,199,988
Expenses
$1,074,064
Net income
$125,924
Balance SheetOperations
YearAssetsLiabilitiesNet AssetsRevenueExpensesNet Income
2024Detailed filing. Detailed filing data is available for this year.$2.22$0.00$2.22$0.94$1.52$0.58
2023Detailed filing. Detailed filing data is available for this year.$2.79$0.04$2.75$0.83$1.29$0.46
2022Facts available. Structured filing facts are available, but richer extracted sections are limited.$3.18$0.05$3.13$1.24$1.22$0.02
2021Detailed filing. Detailed filing data is available for this year.$3.13$0.03$3.10$1.33$1.11$0.21
2020Detailed filing. Detailed filing data is available for this year.$2.88$0.00$2.88$1.45$1.45$0.00
2019Detailed filing. Detailed filing data is available for this year.$2.89$0.00$2.89$1.56$0.84$0.72
2018Detailed filing. Detailed filing data is available for this year.$2.20$0.00$2.20$1.20$1.07$0.13
2017Detailed filing. Detailed filing data is available for this year.$2.11$0.02$2.09$1.68$0.92$0.76
2016Detailed filing. Detailed filing data is available for this year.$1.34$0.00$1.34$0.60$0.87$0.27
2015Summary only. Only limited summary data is available for this year.$1.61$0.00$1.61$1.56$0.56$1.00
2014Detailed filing. Detailed filing data is available for this year.$0.60$0.00$0.60$0.66$0.06$0.60